Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer's disease.

ABSTRACT:

Objectives

To assess the cost-effectiveness of aducanumab at its updated price for treating patients with mild cognitive impairment (MCI) and mild Alzheimer's disease (AD).

Design

Cost-effectiveness analysis.

Settings

A five-state Markov model was constructed using 10 000 virtual patients to assess the cost-effectiveness of aducanumab from the perspective of the US healthcare system. The model employed a one-year cycle time and a lifetime time horizon. Transition probabilities and mortality rates were derived from a literature review. To address uncertainty and generalise the base case results, both one-way and probabilistic sensitivity analyses were conducted.

Participants

10 000 virtual patients with MCI and mild AD.

Interventions

The study group consi

SUBMITTER: Xiong X 

PROVIDER: S-EPMC12007052 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature